Ads
related to: sickle cell disease treatment- Treatment Journey
See the treatment journey
Step by step.
- Mechanism of Action Video
Watch an MOA video on the
official HCP website.
- Stay Informed
Sign up to receive updates
as they become available.
- Resources
Downloadable HCP brochure
and more professional resources.
- Treatment Journey Video
See the treatment journey
video on the HCP website.
- About The Therapy
The science behind the disease
and this treatment option.
- Treatment Journey
Search results
Results From The WOW.Com Content Network
By comparison, research earlier this year showed medical expenses for current sickle cell treatments, from birth to age 65, add up to about $1.6 million for women and $1.7 million for men.
Hydroxycarbamide. Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, essential thrombocythemia, chronic myelogenous leukemia, polycythemia vera, and cervical cancer. [3] [4] In sickle-cell disease it increases fetal hemoglobin and decreases the number of attacks. [3] It is taken by mouth.
It may cause a low white blood cell count, which can predispose the person to some types of infection. Treatment. Broad spectrum antibiotics to cover common infections such as Streptococcus pneumoniae and mycoplasma, pain control, and blood transfusion. Acute chest syndrome is an indication for exchange transfusion. [citation needed]
Sickle cell-Hb Lepore Boston syndrome is a type of sickle cell disease (HbS) that differs from homozygous sickle cell disease where both parents carry sickle hemoglobin. In this variant one parent has the sickle cell hemoglobin the second parent has Hb Lepore Boston, the only one of the three variants described in association with HbS.
Treatment is the same as for patients with sickle cell disease. Patients may receive hydroxyurea to induce the protective effects of increased fetal hemoglobin production. They may also benefit from blood transfusions especially during vaso-occlusive crises.
Identifiers. DrugBank. DB15572. UNII. S53L777GM8. KEGG. D12749. Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy used for the treatment of sickle cell disease [1] [3] and transfusion-dependent beta thalassemia. [1] It was developed by Vertex Pharmaceuticals and CRISPR Therapeutics.
Sickle cell anemia. In sickle cell anemia, treatment is initially with intravenous fluids, pain medication, and oxygen therapy. The typical treatment of priapism may be carried out as well. Blood transfusions are not usually recommended as part of the initial treatment, but if other treatments are not effective, exchange transfusion may be done.
Beyond the impact to one’s health, the lifetime cost of treating a patient with sickle cell disease can be $4 to $6 million — despite a median age of death of only 45 years old. And that doesn ...
Ads
related to: sickle cell disease treatment